PROBIOTIX HEALTH LS-05 (X90) - Total Liabilities
Based on the latest financial reports, PROBIOTIX HEALTH LS-05 (X90) has total liabilities worth €591.00K EUR (≈ $690.94K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore X90 net assets growth trend to track the company's year-over-year net asset growth rate.
PROBIOTIX HEALTH LS-05 - Total Liabilities Trend (2022–2024)
This chart illustrates how PROBIOTIX HEALTH LS-05's total liabilities have evolved over time, based on quarterly financial data.
PROBIOTIX HEALTH LS-05 Competitors by Total Liabilities
The table below lists competitors of PROBIOTIX HEALTH LS-05 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WhiteSmoke Software Ltd
TA:WSMK
|
Israel | ILA847.00K |
|
Thunderful Group AB
ST:THUNDR
|
Sweden | Skr172.90 Million |
|
All In FutureTech Alliance Inc.
NASDAQ:AIFA
|
USA | $35.21 Million |
|
ELL ENVIRON.HLDGS HD-0001
F:6EL
|
Germany | €263.91 Million |
|
Acceleware Ltd
V:AXE
|
Canada | CA$6.75 Million |
|
TalkPool AG
ST:TALK
|
Sweden | Skr4.46 Million |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
Greece | €45.05 Million |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
USA | $1.06 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down PROBIOTIX HEALTH LS-05's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see X90 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PROBIOTIX HEALTH LS-05's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PROBIOTIX HEALTH LS-05 (2022–2024)
The table below shows the annual total liabilities of PROBIOTIX HEALTH LS-05 from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €254.00K ≈ $296.95K |
-60.37% |
| 2023-12-31 | €641.00K ≈ $749.40K |
+82.67% |
| 2022-12-31 | €350.91K ≈ $410.25K |
-- |
About PROBIOTIX HEALTH LS-05
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and … Read more